Becker's Hospital Review

The value of early intervention with Collagenase SANTYL Ointment

A large-scale, real-world analysis of 15,639 patients treated with Collagenase SANTYL Ointment underscores the clinical and economic benefits of early enzymatic debridement in wound management. Using ...
Yahoo Finance

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a ...
Fierce Healthcare

Optimizing Wound Management: Clinical Evidence, Real-World Data, and Cost Benefits of Collagenase SANTYL Ointment

Recent research is revealing key insights about the therapeutic potential of clostridial collagenase. Join us for this upcoming webinar to learn about new data on SANTYL® ointment’s unique mechanisms ...
Seeking Alpha

MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study

YAVNE, Israel, Feb. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the results of head-to-head ...
Nasdaq

MediWound Ltd. Publishes Post Hoc Analysis Comparing EscharEx® and Collagenase Ointment in Wounds Journal

MediWound Ltd. announced the publication of a peer-reviewed post hoc analysis in the journal Wounds, based on data from its Phase II ChronEx clinical trial for patients with venous leg ulcers (VLUs).